'But it got worse. The fatigue – the same fatigue I'd ironically gone to the GP for in the first place – got worse. I ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy do not address the problem fueling the global obesity crisis: our ...

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

As we have entered into the new year 2025, here's a recap of 2024's economy and healthcare with key areas to look in global ...

As the drugs have gained name recognition among adults, they’ve also become increasingly popular with children and adolescents. But are the safe?

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just ...